Harrow, Inc. (NASDAQ:HROW) Stake Cut by Royce & Associates LP

Royce & Associates LP reduced its holdings in Harrow, Inc. (NASDAQ:HROW) by 33.3% in the 3rd quarter, Holdings Channel reports. The fund owned 360,320 shares of the company’s stock after selling 179,580 shares during the period. Royce & Associates LP’s holdings in Harrow were worth $16,200,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. nVerses Capital LLC purchased a new stake in Harrow in the 2nd quarter worth about $33,000. Allspring Global Investments Holdings LLC lifted its stake in Harrow by 2,730.7% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock worth $44,000 after acquiring an additional 2,048 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Harrow by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock worth $57,000 after acquiring an additional 227 shares in the last quarter. Hills Bank & Trust Co purchased a new stake in Harrow in the 3rd quarter worth about $107,000. Finally, Huntington National Bank purchased a new stake in Harrow in the 3rd quarter worth about $164,000. 72.76% of the stock is owned by hedge funds and other institutional investors.

Harrow Stock Performance

Shares of NASDAQ HROW opened at $39.01 on Friday. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.43 and a current ratio of 2.60. The firm has a market cap of $1.38 billion, a price-to-earnings ratio of -41.50 and a beta of 0.76. The business’s 50-day simple moving average is $47.92 and its 200-day simple moving average is $32.28. Harrow, Inc. has a 52 week low of $8.01 and a 52 week high of $59.23.

Analyst Upgrades and Downgrades

HROW has been the subject of a number of recent research reports. B. Riley reaffirmed a “buy” rating and set a $50.00 price target on shares of Harrow in a research note on Thursday, August 29th. Lake Street Capital raised their price target on Harrow from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, October 4th. Finally, Craig Hallum raised their price target on Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a research note on Friday, October 4th.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.